Thomas Enzler
Clinical Assistant Professor of Internal Medicine
Department of Internal Medicine, Division of Hematology/Oncology
1500 E. Medical Center Dr. SPC 5843
Ann Arbor, MI 48109-5843
[email protected]

Available to mentor
Thomas Enzler
Clinical Assistant Professor
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • Qualifications
    • Fellowship, Hematology and Oncology
      Columbia University Irving Medical Center, Medicine, 2018
    • Residency, Internal Medicine
      University of Arizona College of Medicine, Tucson, 2015
    • Fellowship, Hematology and Oncology
      Universitätsmedizin Göttingen, Medicine, 2013
    • Clinical Training
      Stanford University School of Medicine, Internal Medicine, 2009
    • Postdoctoral Research Fellow
      University of California, San Diego, Pharmacology, 2008
    • Residency, Internal Medicine
      University Hospital of Basel, Medicine, 2000
    • Residency, Internal Medicine
      University Hospital of Zurich, Medicine, 1999
    • PhD Biochemistry/Immunology, Supervisors: Dr. Glenn Dranoff, Dr. Thomas Blankenstein
      Dana Farber Cancer Institute/Free University of Berlin, Kaiserswerther Str. 16-18, 2004
    • MD
      University of Basel Medical School, Klingelbergstr. 61, 1995
    • MS Biochemistry/Organic Chemistry
      ETH Zurich, Zurich, 1988
    • BS
      ETH Zurich, Zurich, 1985
    Center Memberships
    • Center Member
      Rogel Cancer Center
    Research Overview

    My clinical and laboratory research focuses on understanding the mechanisms involved in shaping the tumor immune microenvironment (TIME) and on developing methods to reprogram the TIME with the goal to raise anti-tumor immune responses.
    In my laboratory projects I study the TIME of pancreatic cancer and its precursor lesions, as well as of esophagogastric cancers using computational multiplex immune fluorescence technology, RNA technologies, and organoids.
    In my clinical projects I am involved in designing clinical trials with the use of investigational drugs, which modulate the TIME.

    Recent Publications See All Publications
    • Journal Article
      A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
      Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Ruste SA, Haun A, Kawabe T. Eur J Cancer, 2024 Apr; 201: 113950 DOI:10.1016/j.ejca.2024.113950
      PMID: 38422585
    • Journal Article
      A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
      Enzler T, Shi J, McGue J, Griffith BD, Sun L, Sahai V, Nathan H, Frankel TL. International Journal of Molecular Sciences, 2024 Mar 3; 25 (5): 2953 - 2953.
    • Proceeding / Abstract / Poster
      A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
      Dayyani F, Baretti M, Lee SS, He AR, Kim RD, Lin BS-L, Enzler T, Al Hallak MN, Ulahannan SV, Davis SL, Burgoyne A, Tweardy D, Harding JJ, Kaseb AO, de Achaval S, Alibhai I, Kauh JS. Journal of Clinical Oncology, 2024 Jan 20; 42 (3_suppl): tps577 - tps577. DOI:10.1200/jco.2024.42.3_suppl.tps577
    • Proceeding / Abstract / Poster
      Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata.
      Sahai V, Gunchick V, Paul S, Enzler T, Zalupski M, Frankel T. Journal of Clinical Oncology, 2024 Jan 20; 42 (3_suppl): 704 - 704. DOI:10.1200/jco.2024.42.3_suppl.704
    • Presentation
      Presentation of prospective clinical trials
      Enzler T. 2024 Jan 1;
    • Journal Article
      Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
      Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V. Clin Cancer Res, 2023 Jul 5; 29 (13): 2394 - 2400. DOI:10.1158/1078-0432.CCR-23-0036
      PMID: 37115501
    • Journal Article
      Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
      Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL, Ilson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, Mukherjee S, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA. J Natl Compr Canc Netw, 2023 Apr; 21 (4): 393 - 422. DOI:10.6004/jnccn.2023.0019
      PMID: 37015332
    • Presentation
      Managing Gastrointestinal Impacts of Cancer Treatment
      2023 Mar 23;